Microglial inflammasome activation drives developmental white matter injury

Rebecca K. Holloway1 | Graeme Ireland1 | Gemma Sullivan1 | Julie-Clare Becher2 | Colin Smith3 | James P. Boardman1 | Pierre Gressens4,5 | Veronique E. Miron1

1Medical Research Council Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK
2Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh, Edinburgh, UK
3Centre for Clinical Brain Sciences, Centre for Comparative Pathology, Chancellor's Building, The University of Edinburgh, Edinburgh, UK
4Department of Perinatal Imaging and Health, Rayne's Institute, King's College London, London, UK
5PROTECT, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France

Correspondence
Veronique E. Miron, Medical Research Council Centre for Reproductive Health, The Queen’s Medical Research Institute, The University of Edinburgh, Edinburgh EH16 4TJ, UK.
Email: vmiron@ed.ac.uk

Present address
Graeme Ireland, Aquila Biomedical, 9 Edinburgh Bioquarter, Edinburgh, UK

Funding information
Action Medical Research, Grant/Award Number: GN2318; Medical Research Council Canada, Grant/Award Numbers: MR/M020827/1, MR/N02256/1; Tommy's Baby Charity

Abstract
Injury to the developing brain during the perinatal period often causes hypomyelination, leading to clinical deficits for which there is an unmet therapeutic need. Dysregulation of inflammation and microglia have been implicated, yet the molecular mechanisms linking these to hypomyelination are unclear. Using human infant cerebrospinal fluid (CSF) and postmortem tissue, we found that microglial activation of the pro-inflammatory molecular complex the NLRP3 inflammasome is associated with pathology. By developing a novel mouse brain explant model of microglial inflammasome activation, we demonstrate that blocking the inflammasome rescues myelination. In human and mouse, we discovered a link between the inflammasome product IL1β and increased levels of follistatin, an endogenous inhibitor of activin-A. Follistatin treatment was sufficient to reduce myelination, whereas myelination was rescued in injured explants upon follistatin neutralization or supplementation with exogenous activin-A. Our data reveal that inflammasome activation in microglia drives hypomyelination and identifies novel therapeutic strategies to reinstate myelination following developmental injury.

KEYWORDS
inflammation, microglia, myelination, oligodendrocyte, white matter injury

1 INTRODUCTION

Injury to the infant brain during the perinatal period is the predominant risk factor for development of lifelong deficits in cognition, sensation, or movement (e.g., as seen in cerebral palsy). Common contributors to this injury are infection-induced inflammation and hypoxia, which alter oligodendrocyte precursor responses, including increased proliferation and death, and impaired maturation into myelin-forming oligodendrocytes (Back & Rosenberg, 2014; Hagberg et al., 2015; van Tilborg et al., 2018). The consequent hypomyelination then deprives axons of metabolic/trophic support and insulation for electrical impulse conduction (Back et al., 2001; French, Reid, Mamontov, Simmons, & Grinspan, 2009; Segovia et al., 2008).
This injury is associated with dysregulation of resident macrophages of the central nervous system (CNS) termed microglia (Dommergues, Plaisant, Verney, & Gressens, 2003; Favrais et al., 2011; Hellstrom Erkenstam et al., 2016; Krishnan et al., 2017; Pang, Cal, & Rhodes, 2003; Verney et al., 2012), which show sustained expression of pro-inflammatory factors (e.g., inducible nitric oxide synthase [iNOS] and tumor necrosis factor alpha [TNFα]) (Haynes, Folkert, Trachtenberg, Volpe, & Kinney, 2009; Pang et al., 2003; Yoon et al., 1997). However, the molecular mechanisms linking microglial dysregulation to hypomyelination remain unclear.

Here, we asked whether microglia cause hypomyelination in developing brain via activation of the pro-inflammatory molecular complex the NLRP3 inflammasome, which has been previously linked to both dysregulated microglia activation and white matter injury in the adult CNS (Barclay & Shinohara, 2017; Denker et al., 2007; Inoue, Williams, Gunn, & Shinohara, 2012). We demonstrate microglial activation of the NLRP3 inflammasome to be a key pathological driver of developmental hypomyelination. We also reveal a hitherto unrecognized link between microglial inflammasome activation and regulation of activin-A signaling, which limits developmental myelination after injury. Together, our findings identify novel therapeutic strategies to restore myelination following perinatal brain injury.

2 | MATERIALS AND METHODS

2.1 | Animal husbandry

All experiments were performed under V.E.M.'s United Kingdom Home Office project license issued under the “Animals (scientific procedures) Act 1986” and with approval of the Animal Welfare and Ethics Review Body. Animals were housed in a 12 hr light/dark cycle with unrestricted access to food and water. ARRIVE guidelines have been followed for this study.

2.2 | Organotypic mouse brain explant model

Postnatal day (P)0-P3 CD1 forebrains of male and female pups were coronally sectioned at 300 μm using a McIlwain tissue chopper and plated onto poly-D-lysine and laminin-2-coated (10 μg/ml) Millipore Millicel-CM mesh inserts (Fisher Scientific) at three explants per hypoxic conditions (3% O2) for 3 days until 10 DIV. In a subset of experiments, explants were treated with GdCl3 (270 μM, Sigma), MCC950 (10 μM, Selleck Chemicals), Ac-YVAD (100 μM, Cambridge Bioscience), activin-A (10 ng/ml, R&D systems) or vehicle controls during LPS and hypoxia exposure from 7 to 10 DIV. In a subset of experiments, a follistatin neutralizing antibody (10 μg/ml; R&D Systems) or goat IgG isotype control (10 μg/ml; R&D Systems) was applied during LPS and hypoxia exposure from 7 to 10 DIV, or recombinant follistatin (10 ng/ml; R&D Systems) or vehicle control was applied to uninjured explants from 7 to 10 DIV. Explants were fixed with 4% paraformaldehyde (PFA; Sigma) for 10 min.

2.3 | Immunofluorescent staining of explants

Fixed explants were blocked in 5% normal horse serum (GIBCO) and 0.3% Triton-X-100 (Fisher Scientific) for 1 hr. Primary antibodies diluted in block were applied in a humid chamber at 4°C for 48 hr. Antibodies included mouse anti-O4 (1:100, gift from J. Pound, University of Edinburgh), rat anti-MBP (1:250, AbD Serotec), rabbit anti-Ki67 (1:100, EMD Millipore), mouse anti-Olig2 (1:100, EMD Millipore), rabbit anti-Olig2 (1:100, EMD Millipore), mouse anti-Olig1 (1:100, Millipore), mouse anti-NF2 (1:100, EnCor), mouse anti-iNOS (1:100, BD Biosciences), rabbit anti-NG2 (1:200, EMD Millipore), goat anti-cleaved caspase-1 (p20/m296, 1:100, Santa Cruz Biotechnology), and rat anti-CD68 (1:100, Abcam). Following washes in PBS, secondary antibody diluted in block was applied in a humid chamber at 20–25°C for 2 hr (1:500; Life Technologies-Molecular Probes). To assess cell death, the DeadEND fluorometric TUNEL system (Promega) was used according to the manufacturer’s instructions. Death was further assessed in explants by live incorporation of a marker of compromised membrane integrity, propidium iodide (PI, 25 μg/ml; Sigma-Aldrich), for 1 hr prior to fixation in the dark. Explants were counterstained with Hoechst and mounted onto glass slides using Fluoromount-G (Southern Biotech). Images were captured as Z-stacks using an Olympus 3i Spinning Disk microscope and presented as maximum projections using SlideBook 6 software.

2.4 | Enzyme-linked immunosorbent assay

Levels of TNF-α or follistatin in conditioned media collected from explants were measured by ELISA according to the manufacturer’s instructions (R&D Systems; RayBiotech). Absorbance was read at 450 nm on a spectrophotometer and sample concentrations calculated using the equation generated from the standard curve.

2.5 | Western blotting

Explants were washed in ice-cold PBS, scraped off the mesh into RIPA buffer (Sigma-Aldrich) supplemented with Thermo Scientific Halt protease and phosphatase inhibitor cocktail, and homogenized with a 23-gauge needle. Samples were shaken at 4°C for 30 min, then centrifuged at 13,000 rpm for 10 min at 4°C. Samples were stored at
−80°C until use. Protein concentrations were determined using the BCA Protein Assay Kit (Pierce) according to the manufacturer’s instructions. Samples were diluted in Laemmli buffer (Bio-Rad), supplemented with 5% mercapto-ethanol, and heated at 95°C for 2 minutes. Five microgram of protein per sample was loaded onto 4–15% pre-cast polyacrylamide gels (Bio-Rad). Gel electrophoresis was performed in Tris-hydroxyethyl piperazineethanesulfonic acid (HEPES)-sodium dodecyl sulfate (SDS) running buffer (Thermo Scientific) at 100 V for 45 min. Proteins were transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore) for 2 hr at 10 V in 10% Pierce transfer buffer (Thermo Scientific) and 20% methanol diluted in water. Membranes were blocked with 4% bovine serum albumin (BSA) in Tris-buffered saline with 0.1% Tween-20 (vol/vol) (TBST) for 1 hr at room temperature on an orbital shaker. Rabbit anti-IL1β (1:1000, Abcam) was applied overnight at 4°C, washed thrice in TBST for 10 min and incubated with horseradish peroxidase-conjugated secondary antibody (1:2000; Cell Signalling Technology) for 1 hr at room temperature. Chemiluminescent substrate detection reagent ECL SuperSignal (Thermo Scientific) was applied and digital imaging was performed using the LI-COR Odyssey Fc system. For loading control, membranes were re-blotted with mouse anti-β-actin antibody (1:2000, Cell Signalling Technology) then secondary antibody, and imaged as above.

2.6 Data mining of in vivo mouse model of perinatal brain injury

A microarray gene expression dataset of microglia isolated from a perinatal brain injury model was mined for expression of follistatin.

**FIGURE 1** Microglial inflammasome activation in human perinatal brain injury. (a) Normalized values for IL1β protein levels in CSF of term and preterm infants. Two-tailed Student’s t test, \( p = 0.0468, n = 11 \) preterm, 15 term cases. (b) Non-injured and injured regions of human infant brain stained for MBP (purple) and counterstained with Hoechst (blue). Scale bars, 100 μm. (c) Injured and noninjured regions of human infant brain demonstrating NLRP3 (blue) and CD68 (red) double positive cells (arrows), counterstained with Hoechst (turquoise). Scale bar, 20 μm. (d) Densities of NLRP3+ and CD68+ cells/mm² in healthy control versus injured human infant brain. Paired t-test, \( p = 0.0148, n = 5 \) cases. (e) Densities of iNOS+CD68+ cells/mm² versus ENPP6+ cells/mm² in injured and non-injured regions. Mann–Whitney test, \( p = 0.0451, n = 5 \) control cases and 8 injured cases. (f) Representative images of ENPP6+ cells in injured and non-injured regions of infant brain. Scale bar, 20 μm. (k) Mean gene expression of CASP1, MAG and MOG in human fetal brain at 12 gestational weeks (gw), fold over levels at 9 gestational weeks.
(Fst) (Krishnan et al., 2017). This data was generated following intra-peritoneal injections of recombinant mouse interleukin-1β (10 μg/kg) or PBS vehicle control into male Swiss mice (OF1) twice a day from P1-4 and once at P5. Four hours postinjection, mice were sacrificed by perfusion with 0.9% sodium chloride. Mice were randomly allocated to treatment groups by alternating allocation. Brains were

![Brain explant model of microglia inflammasome activation](image)

(Figure 2) Brain explant model of microglia inflammasome activation. (a) Diagram of mouse forebrain explant model. Explants are isolated from postnatal day 0 pups. At 7 days in vitro (DIV) when oligodendrocyte precursors are abundant, explants are exposed to lipopolysaccharide (LPS) for 2 hr followed by hypoxia (3% O2) for 3 days until 10 DIV. Untreated explants (Unt) mirror in vivo oligodendrocyte maturation, at 7 DIV showing abundance of oligodendrocyte precursors (O4+; magenta) and paucity of myelin (MBP+; magenta) on axons (NF+; green), and myelination then being robust by 21 DIV. Scale bar, 25 μm. (b) Control and LPS/Hypoxia exposed explants at 10 DIV immunostained for cleaved caspase-1 (p20; green) and CD68 (purple), counterstained with Hoechst (blue). Examples of double positive cells are indicated by arrows. Scale bar, 25 μm. (c) Average cleaved caspase-1 (p20)+CD68+ cells/field at 10 DIV. Two-tailed Student’s t test, p = .0018, n = 3–4 mice/group. (d) Western blot of control (Ctrl) or LPS/Hypoxia (L/H)-exposed explants demonstrating pro-IL1β (30 kDa) and mature IL1β (17 kDa), against loading control Actin. (e) Quantification of intensity of mature IL1β signal in western blots normalized to actin signal, represented as relative units. Two-tailed Student’s t test, p = .0340, n = 3 mice/group. (f) Control or LPS/Hypoxia-treated explants at 10 DIV stained for iNOS (green) and CD68 (purple). Examples of double positive cells are indicated by arrows. Scale bar, 25 μm. (g) Mean number of iNOS+CD68+ cells per field in control and LPS/Hypoxia-exposed explants at 10 DIV. Two-tailed Student’s t test, p = .0007, n = 7 mice/group. ND = not detected. (h) Concentration of TNF-α (pg/ml) secreted from control and LPS/Hypoxia-exposed explants from 7 to 10 DIV. Two-tailed Student’s t test, p = 0.0049, n = 3 mice/group. ND = not detected.
dissociated using the Neural Tissue Dissociation Kit containing papain and the gentle MACS Octo Dissociator with Heaters (Miltenyi). Microglia were isolated by magnetic bead associated cell sorting using the CD11B antibody (1:10; Miltenyi) according to the manufacturer's instructions. RNA was extracted and hybridized to Agilent Whole Genome Oligo Microarray (8x60K). Background corrected Log 2

FIGURE 3  White matter pathology in inflammasome-activated brain explants. (a) Oligodendrocyte lineage cell (Olig2+; green) proliferation (Ki67+; red) in control and LPS/Hypoxia-exposed explants at 8 DIV. Examples of double positive cells are indicated by arrows. Scale bar, 25 μm. (b) Mean number of Ki67+ Olig2+ cells per field at 8 DIV in control and LPS/Hypoxia exposed explants. Two-tailed Student's t test, \( p = .0018 \). \( n = 5 \) mice/group. (c) Oligodendrocyte lineage cell (Olig2+; red) apoptosis (TUNEL+; green) in control and LPS/Hypoxia-exposed explants at 8 DIV. Double positive cells indicated by arrows. Scale bars, 10 μm. (d) Mean number of TUNEL+ Olig2+ cells per field at 8 DIV in control and LPS/Hypoxia exposed explants. Two-tailed Student's t test, \( p = .0021 \). \( n = 5 \) mice/group. (e) Mean number of NG2+ or cytoplasmic Olig1 + Olig2+ cells per field at 10 DIV in LPS/Hypoxia-exposed explants normalized to untreated control (dotted line). One sample t test, \( p = .0359 \) (NG2+) and 0.0144 (Olig1 + Olig2+). \( n = 10 \) and 3 mice/group, respectively. (f) OPCs (NG2+; green) in control and LPS/Hypoxia-exposed explants at 10 DIV. Scale bar, 25 μm. (g) Differentiating oligodendrocytes identified by cytoplasmic Olig1 (green) and nuclear Olig2 expression (purple) in control and LPS/Hypoxia-exposed explants at 10 DIV. Scale bar, 25 μm. (h) Myelination index at 10 and 21 DIV in untreated control and LPS/Hypoxia-exposed explants. Two-tailed Student's t test, \( p = .0076 \) and 0.0192, respectively, \( n = 3–5 \) mice/group. (i) Myelination at 21 DIV in explants that were untreated (control) or exposed to LPS/Hypoxia, indicated by MBP (magenta) and NF (green). Scale bar, 20 μm.
intensity data were quantile-normalized and assigned p values based on intensity levels and proximity to baseline, with \( p < .05 \) taken to be statistically significant. Mean expression values from PBS controls were subtracted from the IL-1\( \beta \) value at the respective time point. In the published study, the authors confirmed that the cells isolated for gene expression were microglia by flow cytometry (CD11b\(^+\) CD45\(^{lo}\) F480\(^{hi}\) Ly6G\(^-\)) and were not neutrophils (Ly6G\(^+\)) or monocytes (CD45\(^{hi}\)). Furthermore, qPCR analysis of isolated cells found no expression of genes associated with oligodendrocytes, astrocytes, or neurons (Krishnan et al., 2017).

**FIGURE 4** Legend on next page.
2.7 | Human post-mortem tissue, immunostaining, and image acquisition

All tissue was collected with consent and approved by institutional review boards. Paraffin-embedded tissue was deparaffinized in Histoclear (twice for 10 min) and increasing concentrations of ethanol (100–50%; 5 min each), then washed in 0.1% Tween20 (vol/vol) in Tris Buffered Saline (TBS). Slides were microwaved in Vector Unmasking Solution for 10 min, washed once and endogenous phosphatase and peroxidase activity blocked for 5 min (Bloxall, Vector). Primary antibody diluted in 2.5% Normal Horse Serum (Vector) was applied overnight in a humid chamber at 4°C. Antibodies used included rat anti-myelin basic protein (MBP; 1:250, AbD Serotec), mouse anti-CD68 (1:100, DAKO), rabbit anti-iNOS (1:100, Novus), rabbit anti-NLRP3 (1:100, Novus Biochemicals), and rabbit anti-ENPP6 (1:100, ThermoFisher). Following washes, alkaline phosphatase-conjugated secondary antibody was applied for 30 min at 20–25°C in a humid chamber. Sections were washed in TBS and visualized by Vector Blue substrate kit according to the manufacturer’s instructions (maximum 15 min). For staining, sections were washed thrice and re-blocked to quench residual phosphatase activity (Bloxall, Vector) prior to application of primary antibody, then developed using Vector Red substrate kit according to the manufacturer’s instructions (maximum 15 min). Following washes in water, the sections were counterstained with Hoechst and mounted with Fluoromount-G. Entire tissue sections were imaged using a Zeiss AxioScan SlideScanner. Comparisons were made either to healthy control cases, or between injury and noninjury regions within the same section. Regions of interest were defined for analysis using Zeiss Zen2 software and representative fields of 360 μm x 360 μm were counted, and counts were multiplied to determine density of immunopositive cells per mm².

2.8 | Human infant cerebrospinal fluid analysis

The neonatal cohort used in this study has been previously described (Boardman et al., 2018). Sampling was carried out in accordance with the recommendations of UK National Research Ethics Service and South East Scotland Research Ethics Committee (14/SS/044) with written consent from parents of all subjects. We selected 11 preterm infants and 15 term neonates with a C-Reactive Protein level of >1 mg/L, previously used as a proxy for subclinical inflammation (Fond, Lancon, Auquier, & Boyer, 2018). Infants with CRP >1 mg/L had reduced levels of proteins associated with healthy myelination (IGF1: 0.79 fold; SPP1: 0.64 fold; GAL3: 0.17 fold) suggestive of white matter pathology. For preterm versus term infants, the mean birthweights were 1,026 and 3,473 g, the percentage of males in each cohort was 72 and 80%, and the mean age at birth was 27.24 and 39.96 gestational weeks, respectively. No infants in either group had meningitis. We analyzed data previously generated from a custom antibody array (Tebu-Bio/Ray Biotech) as described previously (Boardman et al., 2018) and used data post-background normalization.

2.9 | Statistics

Volocity 6.3 software (Perkin Elmer) was used to calculate area of co-localization between MBP and neurofilament; these values were normalized to total area of neurofilament to account for variation in axonal densities (“myelination index”). Western blots were quantified using Image Studio Lite v5.2 software. All manual counts were carried out in a blinded manner. Mean ± SEM are shown in graphs. Data handling and statistical processing performed using Microsoft Excel and Graphpad Prism 8 software.

3 | RESULTS

We first asked whether there is differential inflammasome activation in perinatal brain injury compared to healthy development. The NLRP3 inflammasome is composed of NLRP3, a scaffolding protein (ASC), and caspase-1; complex activation leads to production and activation of interleukin-1β (IL1-β). Thus, we compared protein levels

**FIGURE 4** Inflammasome inhibition enhances developmental myelination after injury. (a) Diagram of mouse forebrain explant treatment with LPS/Hypoxia and GdCl₃ or Vehicle control from 7 to 10 DIV. (b) Cleaved-caspase-1 (p20; green) and CD68 (purple) at 10 DIV in LPS/Hypoxia-exposed explants following treatment with Vehicle or GdCl₃. Double positive cells indicated by arrows. Scale bar, 25 μm. (c) Mean cleaved caspase-1 (p20) + CD68+ cells/field at 10 DIV in LPS/Hypoxia-exposed explants following treatment with Vehicle or GdCl₃. Two-tailed Student’s t test, p = 0.0145. n = 3–4 mice/group. (d) Western blot of explant (E) or supernatant (S) lysates following exposure to LPS/Hypoxia and treatment with Vehicle (Veh) or GdCl₃, indicating pro-IL1β (30 kDa) and mature-IL1β (17 kDa) against loading control β-actin. (e) Quantification of intensity of mature IL1β signal in western blots normalized to actin signal, represented as relative units. Two-tailed Student’s t test, p = 0.0131, n = 2 mice/group. (f) LPS/Hypoxia-exposed explants at 10 DIV, treated with vehicle control or GdCl₃ during insult, immunostained for iNOS (green) and CD68 (purple) and counterstained with Hoechst (blue). Double positive cells indicated by arrows. Scale bar, 25 μm. (g) Average iNOS+ CD68+ per field in explants at 10 DIV following treatment with Vehicle or GdCl₃ during LPS/Hypoxia exposure. Two-tailed Student’s t test, p = 0.0428, n = 3 mice/group. (h) Myelination index at 10 DIV for untreated explants and LPS/Hypoxia-exposed explants treated with Vehicle or GdCl₃. Two-tailed Student’s t test, Untreated versus Vehicle p < 0.0001, Vehicle versus GdCl₃ p = 0.0011, n = 5–6 mice/group. (i) MBP (magenta) and NF (green) in LPS/Hypoxia-exposed explants at 10 DIV following treatment with Vehicle or GdCl₃. Scale bar, 25 μm. (j) Myelination index at 10 DIV for LPS/Hypoxia-exposed explants treated with Vehicle, NLRP3 inhibitor MCC950, or caspase-1 inhibitor Ac-YVAD. Student’s t test, Untreated versus Vehicle p = 0.0027, Vehicle versus MCC950 p = 0.0080, Vehicle versus Ac-YVAD p = 0.0036, n = 3–5 mice/group. (k) MBP (magenta) and NF (green) in LPS/Hypoxia-exposed explants at 10 DIV following treatment with Vehicle, NLRP3 inhibitor MCC950, or caspase-1 inhibitor Ac-YVAD. Scale bar, 20 μm.
of IL1β in the cerebrospinal fluid (CSF) of infants at high risk of perinatal brain injury (preterm infants with a birthweight <1,500 g) (Back & Rosenberg, 2014; van Tilborg, de Theije, et al., 2018) to those born at term (Supporting Information, Table S1). IL-1β levels were significantly increased in CSF of preterm versus term infants (Figure 1a). This is consistent with a previous report of increased IL1β detected selectively in damaged white matter of infant postmortem brain, which was most pronounced in preterm infants (Girard, Sebire, & Kadhim, 2010). To determine whether inflammasome activation was associated with microglia, we examined postmortem tissue of infants with recent white matter injury (Table S2: myelin basic protein [MBP] staining indicated in Figure 1b). We found that injured regions had increased densities of inflammasome-activated (NLRP3+) microglia/macrophages (CD68+) compared to uninjured regions (Figure 1c,d).
IL1β induces pro-inflammatory responses in surrounding cells; accordingly, iNOS+CD68+ cell densities were significantly elevated in white matter of infants with injury compared to control infants who died without a primary neuropathological disease (Figure 1e,f), suggesting a pro-inflammatory microglia response. NLRP3+CD68+ cell densities were positively correlated with those of immature oligodendrocytes (ENPP6+) in injured regions (Figure 1g,h) but not in noninjured regions (Figure 1g). Conversely, NLRP3+CD68+ cell densities were not positively correlated with those of mature oligodendrocytes (MBP+) (Figure S1), suggesting an association between microglial inflammasome activation and a block in generation of mature myelinating oligodendrocytes. Consistent with this postulate, data-mining of gene expression profiles of developing human fetal brain (Lindsay et al., 2016) indicated that the gene for caspase-1 (CASP1: \( p = 1.14 \times 10^{-12} \)) is downregulated concomitant with upregulation of myelin genes (MAG: \( p = 2.88 \times 10^{-7} \); MOG: \( p = 1.41 \times 10^{-6} \)) (Figure 1i). Altogether, these data suggest that microglial inflammasome activation in perinatal brain injury may impede healthy myelination.

To test this postulate, we developed an ex vivo organotypic mouse brain explant model of microglial inflammasome activation in the corpus callosum—a white matter tract commonly affected in injured infants (Figure 2a). Uninjured explants mirrored in vivo development, with abundance of oligodendrocyte precursors (O4+) at 7 days in vitro (DIV) and robust myelination by 21 DIV (Figure 2a). We aimed to activate the inflammasome in explants using stimuli previously associated with both inflammasome activation and developmental white matter injury: a component of the gran-negative bacterial cell wall (lipopolysaccharide; LPS) and hypoxia (Barnett et al., 2018; Coumans et al., 2003; Dean et al., 2011; Jiang, Stone, Geng, & Ding, 2018; Juliana et al., 2012; van Tilborg et al., 2018). This combination of insults has translational relevance, as gran-negative bacterial infection is associated with neonatal sepsis, hypomyelination, and development of cerebral palsy (Allard, Brochu, Bergeron, Segura, & Sebire, 2019; Zaidi, Thaver, Ali, & Khan, 2009; Zea-Vera & Ochoa, 2015), and co-existing infection and birth asphyxia increases the risk of developmental brain injury compared to either insult alone (Grether & Nelson, 1997; Hayes et al., 2013; Nelson & Grether, 1998; van Tilborg, Achterberg, et al., 2018; Wu et al., 2003). Accordingly, experimental exposure to LPS followed by hypoxia induces white matter injury in the developing brain (Bonestroo, Heijnen, Groenendaal, van Bel, & Nijboer, 2015; Eklind et al., 2001; Kendall et al., 2011; Martinello et al., 2019; Osredkar et al., 2014; Wang et al., 2009). We applied these insults serially, postulating that this would lead to inflammasome activation which requires two successive signals: an initial stimulus to induce NLRP3 and pro-IL1β expression, and a subsequent stimulus to activate and cleave caspase-1(“p20”), which in turn cleaves IL1β to its mature form. This paradigm was initiated at seven DIV when oligodendrocyte precursors are most abundant, to mimic the timing of injury in human infants. LPS application for 2 hr followed by hypoxia for 3 days (Figure 2a) induced cleaved-caspase-1(p20) primarily in microglia (CD68+), and cleaved-caspase-1(p20)+CD68+ cells were significantly increased compared to control at 10 DIV (Figure 2b,c). Inflammasome activation was confirmed by western blotting of explant lysates, which indicated increased pro- and mature-IL1β following LPS and hypoxia exposure (Figure 2d,e). This was associated with increased iNOS+CD68+ microglia (Figure 2f,g) and secretion of TNFα (Figure 2h), suggesting a pro-inflammatory microglial response.

We then asked whether this microglial inflammasome activation in the explant model was associated with white matter pathology. We found that compared to control, LPS and hypoxia treatment significantly increased oligodendrocyte lineage cell (Olig2+) proliferation (Ki67+) and death (TUNEL+) 1 day later (8 DIV) (Figure 3a–d; Figure 5a,b); increased death was confirmed by live incorporation of a marker of compromised membrane integrity, propidium iodide (Figure 5c,d). This was followed by impaired oligodendrocyte differentiation by 10 DIV, as indicated by increased oligodendrocyte progenitors (NG2+) and decreased differentiating oligodendrocytes.

**FIGURE 5** Link between inflammasome activation and inhibition of activin receptor axis in developmental white matter injury. (a) Correlation between IL1β and follistatin normalized protein values in preterm (magenta) and term (black) human infant cerebellar spinal fluid (CSF). (b) Normalized value of follistatin protein in term and preterm human CSF. Mann–Whitney test, \( p = .0047 \), \( n = 11 \) preterm, 15 term cases. (c) Diagram of in vivo model of perinatal brain injury induced by intraperitoneal injections of IL1β from postnatal day (P) 1 through 5, with hypomyelination observed by P10. (d) Fold change in expression of the follistatin gene (Fst) in microglia following IL1β treatment in vivo compared to PBS-injected control, at P1, P5, and P10. (e) Mean follistatin levels (pg/ml) in conditioned media of 10 DIV explants which were untreated or exposed to LPS/Hypoxia. Student’s t test, \( p = .00255 \), \( n = 3 \) mice per condition. (f) Diagram of treatment of healthy explants or LPS/Hypoxia-exposed explants with recombinant follistatin or vehicle from 7 to 10 DIV. (g) MBP (purple) and NF (green) in explants with no injury at 10 DIV following treatment with Vehicle or Follistatin. Scale bar, 20 μm. (h) Myelination index at 10 DIV for explants without injury or those exposed to LPS/Hypoxia and treated with Follistatin, normalized to values from vehicle control in each respective condition (dotted line). One sample t-test against value of 1. No injury \( p = .0188 \), LPS/Hypoxia \( p = .0030 \), \( n = 3 \) mice/group. (i) Diagram of treatment of explants with anti-follistatin IgG or isotype IgG during LPS/Hypoxia exposure from 7 to 10 DIV. (j) MBP (purple) and NF (green) in LPS/Hypoxia-exposed explants at 10 DIV following treatment with Anti-Follistatin IgG or control Isotype IgG. Scale bar, 20 μm. (k) Myelination index at 10 and 21 DIV in LPS/Hypoxia-exposed explants treated with anti-Follistatin IgG, normalized to values from isotype IgG control at each time point (dotted line). One sample t-test against value of 1, \( p = .0276 \), \( n = 3 \) mice/group. (l) Diagram of treatment of explants with recombinant activin-A or vehicle control during LPS/Hypoxia exposure from 7 to 10 DIV. (m) Myelination index at 21 DIV of untreated explants or those exposed to LPS/Hypoxia and treated with either vehicle or activin-A from 7 to 10 DIV. Two-tailed Student’s t test, Untreated versus Vehicle \( p = .0014 \), Vehicle versus Activin-A \( p = .0063 \), \( n = 5–10 \) mice/group. (n) LPS/Hypoxia-treated explants treated with vehicle control or activin-A and stained for MBP (purple) and neurofilament (green) at 21 DIV. Scale bar, 75 μm.
cytoplasmic Olig1+ Olig2+ relative to control (Figure 3e–g); all NG2+ cells in the explant corpus callosum were positive for the oligodendrocyte lineage marker Olig2 (Figure S2d). In contrast, treatment with LPS or hypoxia alone had no impact on oligodendrocyte lineage cell number, proliferation, or differentiation (Figure S2f–h), consistent with previous findings (van Tilborg, Achterberg, et al., 2018). The combination of LPS and hypoxia treatment caused hypomyelination by 10 and 21 DIV, as quantified by area of co-localization between myelin protein (MBP) and the axonal marker neurofilament (NF), normalized to total NF area (“myelination index”; Figure 3h–i).

Having developed a model showing microglial inflammasome activation and hypomyelination, we then tested whether there was a causal relationship between the two findings. We applied gadolinium chloride (GdCl3) which inhibits the inflammasome and reduces pro-inflammatory microglia activation following white matter damage (Kim, Kim, & Lee, 2015; Miron et al., 2013; Van Steenwinckel et al., 2019; Xu et al., 2017). GdCl3 treatment of explants during LPS and hypoxia exposure (Figure 4a) impaired inflammasome activation in microglia, as indicated by reduced numbers of cleaved caspase-1 (p20)+ CD68+ cells (Figure 4b,c). Western blotting of explant lysates (“E”; Figure 4d) indicated that although pro-IL1β was not affected by GdCl3, mature IL1β was reduced compared to vehicle control (Figure 4e). This was not due to increased secretion of mature IL1β out of the explants as it was largely absent from supernatant lysates (“S”; Figure 4d), likely due to cellular uptake within the explant. iNOS +CD68+ microglia were decreased following GdCl3 treatment (Figure 4f,g), whereas total numbers of CD68+ cells were unaltered compared to vehicle control (Figure S3). GdCl3-treated explants demonstrated enhanced myelination by 10 DIV compared to explants exposed to LPS/Hypoxia and vehicle (Figure 4h,i). We confirmed that inhibition of the microglial inflammasome could rescue myelination by application of specific inhibitors of NLRP3 (MCC950) and cleaved caspase-1 (Ac-YVAD) and found that myelination indices were significantly increased at 10 DIV compared to LPS/Hypoxia and vehicle-treated explants (Figure 4j,k). These findings indicate that inflammasome activation in microglia causes hypomyelination.

We next sought to determine how microglial inflammasome activation inhibits myelination. We previously identified five proteins which are highly significantly altered in preterm versus term CSF (C5a, IL9, Fasl, follistatin, and SPP1) (Boardman et al., 2018), and asked whether these were correlated with levels of IL1β. Whereas in preterm infants, there was poor correlation between IL1β and C5a ($r^2 = 0.2863$), IL9 ($r^2 = 0.04792$), Fasl ($r^2 = 0.01415$), and SPP1 ($r^2 = 0.4192$) (Figure S4), we found a robust correlation with levels of follistatin ($r^2 = 0.7249$) (Figure 5a); there was, however, poor correlation between IL1β and follistatin in term controls ($r^2 = 0.2030$; Figure 5a). In addition, follistatin protein values were significantly increased in preterm versus term infant CSF (Figure 5b), associating it with increased risk of brain injury. We then asked whether IL1β can induce follistatin expression in microglia. We examined published transcriptomes of microglia from an in vivo model which mimics downstream inflammasome activation by injection of IL1β in mice from postnatal day (P)1 through 5, inducing hypomyelination by P10 (Figure 5c) (Krishnan et al., 2017). We found that IL1β exposure in vivo increased follistatin (Fst) levels in microglia by P5 and P10 (Figure 5d). In our explant model, we found increased follistatin protein levels in the conditioned media following treatment with LPS and hypoxia compared to control at 10 DIV (Figure 5e), a time when we observed increased inflammasome activation in microglia. Given that follistatin specifically inhibits activin-A from binding its receptors, and we recently showed that activin-A signaling is required for myelination in development (Dillenburg et al., 2018), we postulated that increased follistatin could impede myelination. Indeed, treating healthy explants with recombinant follistatin from 7 to 10 DIV (Figure 5f) was sufficient to significantly reduce the myelination index at 10 DIV (Figure 5g,h). Additionally, hypomyelination at 10 DIV following LPS and hypoxia exposure was worsened with follistatin treatment (Figure 5h). We then asked whether we could alleviate the detrimental effect of follistatin on myelination in injured explants, using two different approaches. First, we blocked follistatin in injured explants by applying a neutralizing antibody during LPS and hypoxia exposure (Figure 5i). We found that blocking follistatin enhanced myelination compared to LPS and hypoxia-exposed explants treated with isotype IgG control (Figure 5j,k), which reached significance by 21 DIV. Second, we asked whether supplementing injured explants with exogenous activin-A (Figure 5i) could overwhelm the follistatin to allow myelination to take place. We found that activin-A treatment of LPS and hypoxia-exposed explants enhanced myelination index by 21 DIV (Figure 5m,n). These findings reveal an unexpected link between microglial inflammasome activation and activin-A signaling.

**4 | DISCUSSION**

By analysis of human infant brain tissue and cerebral spinal fluid combined with the use of a novel explant model of perinatal brain injury, we reveal that developmental hypomyelination is driven by microglial activation of the NLRP3 inflammasome (see Table of Contents Image). This builds on previous work demonstrating that exogenous application of the inflammasome product IL1β is sufficient to induce hypomyelination in experimental models (Favrais et al., 2011; Krishnan et al., 2017; Mairesse et al., 2019), and that human genetic mutations in NLRP3 causing excess IL1β production are associated with neonatal periventricular white matter lesions (Goldbach-Mansky et al., 2006). We now demonstrate that inflammasome inhibition reinstates myelination in developing white matter, a strategy previously shown to dampen injury to neurons in development (Chen, Xu, & Yuan, 2018; Girard et al., 2012; Leitner et al., 2014) and to white matter in adulthood (Cantuti-Castelvetri et al., 2018; Malhotra et al., 2020).

Microglial inflammasome activation in infants may occur due to exposure to two insults within a short time window to provide priming and activation signals. Accordingly, compound insults in infants are associated with severe white matter injury and increased risk of developing cerebral palsy (Barnett et al., 2018; Grether & Nelson, 1997; Hayes et al., 2013; Nelson & Grether, 1998; Wu et al., 2003). Furthermore, clinical contexts often associated with
perinatal brain injury—systemic infection, encephalopathy and ischemic stroke—would be predicted to provide signals which induce inflammasome activation, such as pathogen-associated molecular patterns, hypoxia, reactive oxygen and nitrogen species, and calcium fluxes (Hagberg et al., 2015; Yang, Wang, Kouadir, Song, & Shi, 2019). This postulate was affirmed by our demonstration that sequential exposure to the gram-negative E. coli cell wall component LPS and hypoxia was sufficient to induce inflammasome activation in microglia in developing white matter. Additionally, recent work demonstrated that although exposure of developing mouse brain explants to LPS alone primes the inflammasome, it does not lead to inflammasome activation nor mature IL1β production (Hoyle et al., 2020), presumably missing the second stimulus for full inflammasome complex activation.

Consistent with this finding, we observed that a combination of LPS and hypoxia was needed to significantly impact the oligodendrocyte lineage, leading to hypomyelination. This is of translational relevance, as gram-negative bacterial infection contributes to hypomyelination and development of cerebral palsy, and co-existing infection and birth asphyxia significantly increase the risk of perinatal brain injury and cerebral palsy compared to either insult in isolation (Allard et al., 2019; Grether & Nelson, 1997; Hayes et al., 2013; Nelson & Grether, 1998; Wu et al., 2003). Previous experimental work in various models (rodent, sheep, piglet) have shown that LPS sensitizes the brain to subsequent hypoxia to exacerbate developmental brain injury (Bonestroo et al., 2015; Eklind et al., 2001; Kendall et al., 2011; Martinello et al., 2019; Osredkar et al., 2014; Wang et al., 2009). Altogether, this demonstrates that the combination of LPS and hypoxia induces microglial inflammasome activation, which drives white matter pathology similar to that observed in human infants with perinatal brain injury.

We reveal that microglial inflammasome activation induces white matter pathology via regulation of the activin receptor axis. We found a correlation between IL1β and increased levels of the endogenous activin-A inhibitor follistatin in the context of human and mouse developing white matter injury. IL1β is known to modulate follistatin levels and activin receptor signaling in skin and the reproductive system (Arai et al., 2011; Bilezikjian et al., 1998), and here we implicate the crosstalk between these pathways in microglia-driven hypomyelination. We complement our previous work showing that activin receptor signaling is required for myelination in development (Dillenburg et al., 2018), by now demonstrating that increased follistatin levels following perinatal brain injury impair myelination. Poor myelination was overcome by neutralizing follistatin or supplementation with exogenous activin-A. This leads to the postulate that reinstating activin receptor signaling could represent a promising therapeutic strategy to promote healthy white matter development in injured infants.

Overall, our findings identify a molecular link between dysregulated microglia activation and hypomyelination in perinatal brain injury, and point to novel therapeutic strategies to support white matter health in injured infants centered on inflammasome inhibition and/or reinstatement of activin receptor signaling.

ACKNOWLEDGEMENTS

The authors thank the Medical Research Council Brain Bank, INSERM-Université Paris Diderot, and David Rowitch and Stephen Fancy from the Newborn Brain Research Institute (UCSF) for providing human postmortem tissue. The authors also thank Rozalia Pataky, Sharan Mahtani, Bobbi Fleiss, Patricia Nimmo, Karina McDade, and Hui-Hsin Tsai for technical support. This project was supported by Action Medical Research/The Rooney Foundation via the Kent Community Foundation (V.E.M., P.G; GN2318), Tommy’s the Baby Charity (V.E.M.), a Medical Research Council Career Development Award (V.E.M.; MR/M020827/1), and funds from the Medical Research Council Centre for Reproductive Health (MR/N02256/1). Diagrams were created using BioRender.com.

DATA AVAILABILITY STATEMENT

All data is available from the corresponding author upon request.

ORCID

Veronique E. Miron https://orcid.org/0000-0003-1738-0647

REFERENCES

Allard, M. J., Brochu, M. E., Bergeron, J. D., Segura, M., & Sebire, G. (2019). Causal role of group B streptococcus-induced acute chorioamnionitis in intrauterine growth retardation and cerebral palsy-like impairments. Journal of Developmental Origins of Health and Disease, 10(S), 595–602. https://doi.org/10.1017/S2040174419001083

Arai, K. Y., Ono, M., Kudo, C., Fujioka, A., Okamura, R., Nomura, Y., & Nishiyama, T. (2011). IL-1beta stimulates activin betaA mRNA expression in human skin fibroblasts through the MAPK pathways, the nuclear factor-kappaB pathway, and prostaglandin E2. Endocrinology, 152(10), 3779–3790. https://doi.org/10.1210/en.2011-0255

Back, S. A., Luo, N. L., Borenstein, N. S., Levine, J. M., Volpe, J. J., & Kinney, H. C. (2001). Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury. The Journal of Neuroscience, 21(4), 1302–1312.

Back, S. A., & Rosenberg, P. A. (2014). Pathophysiology of glia in perinatal white matter injury. Glia, 62(11), 1790–1815. https://doi.org/10.1002/glia.22658

Barclay, W., & Shinohara, M. L. (2017). Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Brain Pathology, 27(2), 213–219. https://doi.org/10.1111/bpa.12477

Barnett, M. L., Tusor, N., Ball, G., Chew, A., Falconer, S., Aljabar, P., ... Counsell, S. J. (2018). Exploring the multiple-hit hypothesis of preterm white matter damage using diffusion MRI. NeuroImage, Clinical, 17, 596–606. https://doi.org/10.1016/j.nic.2017.11.017

Bilezikjian, L. M., Turnbull, A. V., Corrigan, A. Z., Blount, A. L., Rivier, C. L., & Vale, W. W. (1998). Interleukin-1beta regulates pituitary follistatin and inhibin/activin betaB mRNA levels and attenuates FSH secretion in response to activin-A. Endocrinology, 139(7), 3361–3364. https://doi.org/10.1210/endo.139.7.6190

Boardman, J. P., Ireland, G., Sullivan, G., Pataky, R., Fleiss, B., Gressens, P., & Miron, V. (2018). The cerebrospinal fluid inflammatory response to preterm birth. Frontiers in Physiology, 9, 1299. https://doi.org/10.3389/fphys.2018.01299

Bonestroo, H. J., Heijnen, C. J., Groenendaal, F., van Bel, F., & Nijboer, C. H. (2015). Development of cerebral gray and white matter injury and cerebral inflammation over time after inflammatory perinatal asphyxia. Developmental Neuroscience, 37(1), 78–94. https://doi.org/10.1159/000368770

Cantuti-Castelvetri, L., Fitzer, D., Bosch-Queralt, M., Weil, M. T., Su, M., Sen, P., ... Simons, M. (2018). Defective cholesterol clearance limits
remyelination in the aged central nervous system. Science, 359(6376), 684–688. https://doi.org/10.1126/science.aan4183

Chen, A., Xu, Y., & Yuan, J. (2018). Ginkgolide B ameliorates NLRP3 inflammasome activation after hypoxic-ischemic brain injury in the neonatal male rat. International Journal of Developmental Neuroscience, 69, 106–111. https://doi.org/10.1016/j.jidneu.2018.07.004

Coulam, A. B., Middelkamp, J. S., Garnier, Y., Vaihinger, H. M., Leib, S. L., Von Duering, M. U., ... Berger, R. (2003). Intracisternal application of endotoxin enhances the susceptibility to subsequent hypoxic-ischemic brain damage in neonatal rats. Pediatric Research, 53(5), 770–775. https://doi.org/10.1203/01.PDR.0000093521.40073.82

Dean, J. M., van de Looij, Y., Sizonenko, S. V., Lodygensky, G. A., Lazeyras, F., Bolouri, H., ... Mallard, C. (2011). Delayed cortical impairment following lipopolysaccharide exposure in preterm fetal sheep. Annals of Neurology, 70(5), 846–856. https://doi.org/10.1002/ana.22480

Denker, S. P., Ji, S., Dingman, A., Lee, S. Y., Derugin, N., Dommergues, M. A., Plaisant, F., Verney, C., & Gressens, P. (2003). Early inflammatory disease responsive to interleukin-1beta inhibition. The New England Journal of Medicine, 349(1), 36–47. https://doi.org/10.1056/NEJMoa055137

Grether, J. K., & Nelson, K. B. (1997). Maternal infection and cerebral palsy in infants of normal birth weight. JAMA, 278(3), 207–211.

Hagberg, H., Mallard, C., Ferriero, D. M., Vannucci, S. J., Levison, S. W., Vexler, Z. S., & Gressens, P. (2015). The role of inflammation in perinatal brain injury. Nature Reviews. Neurology, 11(4), 192–208. https://doi.org/10.1038/nrneurol.2015.13

Hayes, B. C., Cooley, S., Donnelly, J., Doherty, E., Grehan, A., Madigan, C., ... King, M. D. (2013). The placenta in infants >36 weeks gestation with neonatal encephalopathy: A case control study. Archives of Disease in Childhood. Fetal and Neonatal Edition, 98(3), F233–F239. https://doi.org/10.1136/archdischild-2012-301992

Haynes, R. L., Folkert, R. D., Trachtenberg, F. L., Volpe, J. J., & Kinney, H. C. (2009). Nitrosative stress and inducible nitric oxide synthase expression in periventricular leukomalacia. Acta Neuropathologica, 118(3), 391–399. https://doi.org/10.1007/s00401-009-0540-1

Hellstrom Erkenstam, N., Smith, P. L., Fleiss, B., Nair, S., Svedin, P., Wang, W., ... Mallard, C. (2016). Temporal characterization of microglia/macrophage phenotypes in a mouse model of neonatal hypoxic-ischemic brain injury. Frontiers in Cellular Neuroscience, 10, 286. https://doi.org/10.3389/fncel.2016.00286

Hoyle, C., Redondo-Castro, E., Cook, J., Tzeng, T. C., Allan, S. M., Brough, D., & Lemarchand, E. (2020). Hallmarks of NLRP3 inflammasome activation are observed in organotypic hippocampal slice culture. Immunology, 161(1), 39–52. https://doi.org/10.1111/imm.13221

Inoue, M., Williams, K. L., Gunn, M. D., & Shinohara, M. L. (2012). NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America, 109(26), 10480–10485. https://doi.org/10.1073/pnas.1201836109

Jiang, Q., Stone, C. R., Geng, X., & Ding, Y. (2018). Hypoxia-inducible factor-1 alpha and RIP3 triggers NLRP3 inflammasome in ischemic stroke. Brain Circulation, 4(4), 191–192. https://doi.org/10.4103/bc.bc_35_18

Juliana, C., Fernandes-Alnemri, T., Kang, S., Farias, A., Qin, F., & Alnemri, E. S. (2012). Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. The Journal of Biological Chemistry, 287(43), 36617–36622. https://doi.org/10.1074/jbc.M112.407130

Kendall, G. S., Hristova, M., Horn, S., Dafou, D., Acosta-Saitos, A., Almolda, B., ... Raivich, G. (2011). TNF gene cluster deletion abolishes lipopolysaccharide-mediated sensitization of the neonatal brain to hypoxic ischemic insult. Laboratory Investigation, 91(3), 328–341. https://doi.org/10.1038/labinvest.2010.192

Kim, H. Y., Kim, S. J., & Lee, S. M. (2015). Activation of NLRP3 and AIM2 inflammasomes in Kupffer cells in hepatic ischemia/reperfusion. The FEBBS Journal, 282(2), 259–270. https://doi.org/10.1111/febs.13123

Krishnan, M. L., Van Steenwinckel, J., Schang, A. L., Yan, J., Arnadottir, J., Le Charpentier, T., ... Gressens, P. (2017). Integrative genomics of microglia implicates DLG4 (PSD95) in the white matter development of preterm infants. Nature Communications, 8(1), 428. https://doi.org/10.1038/s41467-017-00422-w

Leitner, K., Al Shammary, M., McLane, M., Johnston, M. V., Elowitz, M. A., & Burd, I. (2014). IL-1 receptor blockade prevents fetal cortical brain injury but not preterm birth in a mouse model of inflammation-induced preterm birth and perinatal brain injury. American Journal of Reproductive Immunology, 71(5), 418–426. https://doi.org/10.1111/aji.12216

Lindsay, S. J., Xu, Y., Lugo, S. N., Harkin, L. F., Copp, A. J., Gerrelli, D., ... Chinnery, P. F. (2016). HDBP expression: A unique resource for global and individual gene expression studies during early human brain development. Frontiers in Neuroanatomy, 10, 86. https://doi.org/10.3389/fnana.2016.00086

Mairesse, J., Zinni, M., Pansiot, J., Hassan-Abdi, R., Demene, C., Colella, M., ... Baud, O. (2019). Oxytocin receptor agonist reduces perinatal brain...
damage by targeting microglia. Glia, 67(2), 345–359. https://doi.org/10.1002/glia.23546

Malhotra, S., Costa, C., Eixarch, H., Keller, C. W., Amman, L., Martinez-Banaclocha, H., ... Comabolla, M. (2020). NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. Brain, 143(5), 1414–1430. https://doi.org/10.1093/brain/awaa084

Martinello, K. A., Meehan, C., Avdic-Belltheus, A., Lingam, I., Ragab, S., Hristova, M., ... Robertson, N. J. (2019). Acute LPS sensitization and continuous infusion exacerbates hypoxic brain injury in a piglet model of neonatal encephalopathy. Scientific Reports, 9(1), 10184. https://doi.org/10.1038/s41598-019-46488-y

Miron, V. E., Boyd, A., Zhao, J. W., Yuen, T. J., Ruckh, J. M., Shadrach, J. L., ... French-Constant, C. (2013). M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nature Neuroscience, 16(9), 1211–1218. https://doi.org/10.1038/nn.3469

Nelson, K. B., & Grether, J. K. (1998). Potentially asphyxiating conditions and spastic cerebral palsy in infants of normal birth weight. American Journal of Obstetrics and Gynecology, 179(2), 507–513. https://doi.org/10.1016/s0002-9378(98)70387-4

Osredkar, D., Thoresen, M., Maes, E., Flitebo, T., Elstad, M., & Sabir, H. (2014). Hypothermia is not neuroprotective after infection-sensitized neonatal hypoxic-ischemic brain injury. Resuscitation, 85(4), 567–572. https://doi.org/10.1016/j.resuscitation.2013.12.006

Pang, Y., Cai, Z., & Rhodes, P. G. (2003). Disturbance of oligodendrocyte development, hypomyelination and white matter injury in the neonatal rat brain after intracerebral injection of lipopolysaccharide. Brain Research Developmental Brain Research, 140(2), 205–214.

Segovia, K. N., McClure, M., Moravec, M., Luo, N. L., Wan, Y., Gong, X., ... Back, S. A. (2008). Arrested oligodendrocyte lineage maturation in chronic perinatal white matter injury. Annals of Neurology, 63(4), 520–530. https://doi.org/10.1002/ana.21359

Van Steenwinckel, J., Schang, A. L., Krishnan, M. L., Degos, V., Delahaye-Duriez, A., Bokobza, C., ... Gressens, P. (2019). Decreased microglial Wnt/beta-catenin signalling drives microglial pro-inflammatory activation in the developing brain. Brain, 142(12), 3806–3833. https://doi.org/10.1093/brain/awz319

van Tilborg, E., Achterberg, E. J. M., van Kammen, C. M., van der Toorn, A., Groenendaal, F., Dijkhuizen, R. M., ... Nijboer, C. H. A. (2018). Combined fetal inflammation and postnatal hypoxia causes myelin deficits and autism-like behavior in a rat model of diffuse white matter injury. Glia, 66(1), 78–93. https://doi.org/10.1002/glia.23216

van Tilborg, E., de Theije, C. G. M., van Hal, M., Wagenaar, N., de Vries, L. S., Benders, M. J., ... Nijboer, C. H. (2018). Origin and dynamics of oligodendrocytes in the developing brain: Implications for perinatal white matter injury. Glia, 66(2), 221–238. https://doi.org/10.1002/glia.23256

Verney, C., Pogledic, I., Biran, V., Adle-Biassette, H., Fallet-Bianco, C., & Gressens, P. (2012). Microglial reaction in axonal crossroads is a hallmark of noncystic periventricular white matter injury in very preterm infants. Journal of Neuropathology and Experimental Neurology, 71(3), 251–264. https://doi.org/10.1097/NEN.0b013e3182496429

Wang, X., Stridh, L., Li, W., Dean, J., Elmgren, A., Gai, L., ... Mallard, C. (2009). Lipopolysaccharide sensitizes neonatal hypoxic-ischemic brain injury in a MyD88-dependent manner. Journal of Immunology, 183(11), 7471–7477. https://doi.org/10.4049/jimmunol.0900762

Wu, Y. W., Escobar, G. J., Grether, J. K., Croen, L. A., Greene, J. D., & Newman, T. B. (2003). Choriomnionitis and cerebral palsy in term and near-term infants. JAMA, 290(20), 2677–2684. https://doi.org/10.1001/jama.290.20.2677

Xu, Y., Yao, J., Zou, C., Zhang, H., Zhang, S., Liu, J., ... Zhang, W. (2017). Asiatic acid protects against hepatic ischemia/reperfusion injury by inactivation of Kupffer cells via PPARgamma/NLRP3 inflammasome signaling pathway. Oncotarget, 8(49), 86339–86355. https://doi.org/10.18632/oncotarget.21151

Yang, Y., Wang, H., Kouadir, M., Song, H., & Shi, F. (2019). Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death & Disease, 10(2), 128. https://doi.org/10.1038/s41419-019-1413-8

Yoon, B. H., Romero, R., Kim, C. J., Koo, J. N., Choe, G., Syn, H. C., & Chi, J. G. (1997). High expression of tumor necrosis factor-alpha and interleukin-6 in periventricular leukomalacia. American Journal of Obstetrics and Gynecology, 177(2), 406–411.

Zaidi, A. K., Thaver, D., Ali, S. A., & Khan, T. A. (2009). Pathogens associated with sepsis in newborns and young infants in developing countries. The Pediatric Infectious Disease Journal, 28(1 Suppl), S10–S18. https://doi.org/10.1097/INF.0b013e3181958769

Zea-Vera, A., & Ochoa, T. J. (2015). Challenges in the diagnosis and management of neonatal sepsis. Journal of Tropical Pediatrics, 61(1), 1–13. https://doi.org/10.1093/tropej/fmu079

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Holloway RK, Irelan G, Sullivan G, et al. Microglial inflammasome activation drives developmental white matter injury. Glia. 2021;69:1268–1280. https://doi.org/10.1002/glia.23963